Roche Confident Spark Therapeutics Acquisition Will Complete In First Half
Executive Summary
US financial regulators have not been quick at reviewing Roche’s multi-billion dollar acquisition of gene therapy biotech Spark Therapeutics, but it is still on track for completion in the first half of 2019.
You may also be interested in...
When It Comes To FTC M&A Review, The Times May Be A Changin'
Spark signaled in an SEC filing that its merger with Roche could be delayed into 2020, fueling more speculation that FTC is increasing scrutiny over biopharma mergers.
When It Comes To FTC M&A Review, The Times May Be A Changin'
Spark signaled in an SEC filing that its merger with Roche could be delayed into 2020, fueling more speculation that FTC is increasing scrutiny over biopharma mergers.
In Merger Plot Twist, BMS Needs A Buyer For Celgene's Otezla, Raising New Questions
Bristol-Myers will have to divest Celgene's blockbuster psoriasis pill to address concerns raised by the US FTC related to the merger. The news raised questions about whether FTC is giving more scrutiny to pipeline overlap.